In this video, David Williamson reviews some of his favorite biotech firms. Many analysts have thrown their weight behind Biogen and its new BG12 drug for multiple sclerosis. However, David favors Gilead over Biogen since Gilead has a larger, more diverse product pipeline. Celgene is the No. 1 biotech in David's opinion since it also has blockbuster drugs but a PEG of less than 1.0. Amgen is a big company with more products in development than most people realize. Overall, for value and future earnings potential, David likes Celgene the best.
Can Celgene continue to soar?
Every in-the-know biotech investor has an eye on Celgene. Shares have skyrocketed this year as the company outlined a plan to almost triple its profits in only a few years. But should you buy the story Celgene is selling? Make sure you understand the key opportunities and risks facing this company by picking up The Motley Fool's brand-new premium report on Celgene. To claim your copy today, simply click here now.
The article Wall Street Backs the Wrong Biotech originally appeared on Fool.com.
David Williamson has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.